Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer

被引：1

作者：

Cappuccio, Serena ^{[1
]}

Marinucci, Benito ^{[2
]}

Bove, Vincenzo ^{[3
]}

Turco, Luigi Carlo ^{[4
,5
]}

Cosentino, Francesco ^{[5
]}

Scambia, Giovanni ^{[1
,2
]}

Costamagna, Guido ^{[2
,3
]}

Boskoski, Ivo ^{[2
,3
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Dept Womans Childs & Publ Hlth, Rome, Italy

[2] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Rome, Italy

[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Digest Endoscopy Unit, Rome, Italy

[4] Mater Olbia Spa, Gynecol & Breast Care Unit, Olbia, Italy

[5] Univ Cattolica Sacro Cuore, Gynecol Oncol, Gemelli Molise Spa, Campobasso, Italy

来源：

CHEMOTHERAPY | 2020年 / 65卷 / 1-2期

关键词：

Adverse events; Bevacizumab; Endoscopic suture; Gastric perforation; Ovarian cancer; GASTROINTESTINAL PERFORATION; PHASE-3; TRIAL; CHEMOTHERAPY; THERAPY; RISK; COMBINATION; FOCUS;

D O I：

10.1159/000508556

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Antiangiogenic chemotherapy is a common treatment option for patients with advanced ovarian cancer (OC) and has been proven to be effective and generally safe. Nevertheless, in rare cases, these drugs can give serious complications such as gastrointestinal perforations that can be even mortal or very difficult to treat and can heavily impact the clinical management. We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.

引用

页码：54 / 57

页数：4

共 50 条

[31] Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
Zheng, Zhuoling
Zhao, Yihong
Xie, Jingwen
Gao, Min
Wang, Yiting
Li, Xiaoyan
FRONTIERS IN PHARMACOLOGY, 2024, 15
[32] Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort
Odia, Yazmin
Shih, Joanna H.
Kreisl, Teri N.
Fine, Howard A.
JOURNAL OF NEURO-ONCOLOGY, 2014, 120 (02) : 431 - 440
[33] Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study
Akers, S. N.
Riebandt, G.
Miller, A.
Groman, A.
Odunsi, K.
Lele, S.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2013, 34 (02) : 113 - 119
[34] The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Zhang, Wenwen
Shen, Zhaojun
Luo, Hui
Hu, Xiaoli
Zheng, Lihong
Zhu, Xueqiong
CURRENT DRUG TARGETS, 2017, 18 (10) : 1125 - 1131
[35] Superior Anticancer Potential of Nano-Paclitaxel Combined Bevacizumab Treatment in Ovarian Cancer
Qu, Na
Wang, Chunyan
Meng, Yiming
Gao, Yuhua
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2023, 24 (09) : 1204 - 1212
[36] The roles and limitations of bevacizumab in the treatment of ovarian cancer
Hidekatsu Nakai
Noriomi Matsumura
International Journal of Clinical Oncology, 2022, 27 : 1120 - 1126
[37] Critical appraisal of bevacizumab in the treatment of ovarian cancer
Yoshida, Hiroyuki
Yabuno, Akira
Fujiwara, Keiichi
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2351 - 2357
[38] Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort
Yazmin Odia
Joanna H. Shih
Teri N. Kreisl
Howard A. Fine
Journal of Neuro-Oncology, 2014, 120 : 431 - 440
[39] Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
Alfonso De Stefano
Chiara Carlomagno
Stefano Pepe
Roberto Bianco
Sabino De Placido
Cancer Chemotherapy and Pharmacology, 2011, 68 : 1207 - 1213
[40] Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab
Liu, S. V.
Gollard, R.
Iqbal, S.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (05) : 607 - 609

← 1 2 3 4 5 →